Adherence to inhaled corticosteroids and long-acting ?2-agonists in asthma: A MASK-air study

Data de publicação: 01/01/2023 Data Ahead of Print: 03/08/2023

Autores da FMUP

• Bernardo Manuel De Sousa Pinto

  Autor

• Rita Da Silva Amaral

  Autor

• Ana Isabel Alves De Sá E Sousa

  Autor

• João De Almeida Lopes Da Fonseca

  Autor

Participantes de fora da FMUP

• Louis, R
• Anto, JM
• S? Sousa, A
• Czarlewski, W
• Brussino, L
• Canonica, GW
• Chaves Loureiro, C
• Cruz, AA
• Gemicioglu, B
• Haahtela, T
• Kupczyk, M
• Kvedariene, V
• Larenas Linnemann, DE
• Okamoto, Y
• Ollert, M
• Pfaar, O
• Pham Thi, N
• Puggioni, F
• Regateiro, FS
• Romantowski, J
• Sastre, J
• Scichilone, N
• Taborda Barata, L
• Ventura, MT
• Agache, I
• Bedbrook, A
• Becker, S
• Bergmann, KC
• Bosnic Anticevich, S
• Bonini, M
• Boulet, L
• Brusselle, G
• Buhl, R
• Cecchi, L
• Charpin, D
• de Blay, F
• Del Giacco, S
• Ivancevich, JC
• Jutel, M
• Klimek, L
• Kraxner, H
• Kuna, P
• Laune, D
• Makela, M
• Morais Almeida, M
• Nadif, R
• Niedoszytko, M
• Papadopoulos, NG
• Papi, A
• Patella, V
• P?tr?, B
• Rivero Yeverino, D
• Robalo Cordeiro, C
• Roche, N
• Rouadi, PW
• Savour?, M
• Shamji, MH
• Sheikh, A
• Suppli Ulrik, C
• Usmani, OS
• Valiulis, A
• Yorgancioglu, A
• Zuberbier, T
• Costa, EM
• Bousquet, J

Unidades de investigação

• Laboratório Associado RISE- Rede de Investigação em Saúde

  

  Investigador

  Fernando Carlos De Landér Schmitt

• Medicina da Comunidade, Informação e Decisão em Saúde

• RISE-Health

  

  Investigador

  Fernando Carlos De Landér Schmitt

Abstract

Introduction: Adherence to controller medication is a major problem in asthma management, being difficult to assess and tackle. mHealth apps can be used to assess adherence. We aimed to assess the adherence to inhaled corticosteroids+long-acting ?2-agonists (ICS+LABA) in users of the MASK-air? app, comparing the adherence to ICS+formoterol (ICS+F) with that to ICS+other LABA. Materials and methods: We analysed complete weeks of MASK-air? data (2015-2022; 27 countries) from patients with self-reported asthma and ICS+LABA use. We compared patients reporting ICS+F versus ICS+other LABA on adherence levels, symptoms and symptom-medication scores. We built regression models to assess whether adherence to ICS+LABA was associated with asthma control or short-acting beta-agonist (SABA) use. Sensitivity analyses were performed considering the weeks with no more than one missing day. Results: In 2598 ICS+LABA users, 621 (23.9%) reported 4824 complete weeks and 866 (33.3%) reported weeks with at most one missing day. Higher adherence (use of medication ?80% of weekly days) was observed for ICS+other LABA (75.1%) when compared to ICS+F (59.3%), despite both groups displaying similar asthma control and work productivity. The ICS+other LABA group was associated with more days of SABA use than the ICS+F group (median=71.4% versus 57.1% days). Each additional weekly day of ICS+F use was associated with a 4.1% less risk in weekly SABA use (95%CI=-6.5;-1.6%;p=0.001). For ICS+other LABA, the percentage was 8.2 (95%CI=-11.6;-5.0%;p<0.001). Conclusions: In asthma patients adherent to the MASK-air app, adherence to ICS+LABA was high. ICS+F users reported lower adherence but also a lower SABA use and a similar level of control. ? 2023 Sociedade Portuguesa de Pneumologia

Copyright © 2023 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. All rights reserved.

Keywords

• Adherence; Asthma; Formoterol; Inhaled corticosteroids; Long-acting-ß2 agonist